Danaher (DHR) PT Raised to $250 at Barclays
Get Alerts DHR Hot Sheet
Price: $234.64 +1.97%
Rating Summary:
29 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
29 Buy, 11 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Danaher (NYSE: DHR) to $250.00 (from $225.00) while maintaining a Overweight rating.
You May Also Be Interested In
- FDA clears Cepheid test that detects four hemorrhagic fever viruses
- Cepheid Receives FDA Clearance for Xpert® Hemorrhagic Fever Panel Test
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share